Profiling poly-substance use typologies in a multi-site cohort of illicit opioid and other drug users in Canada - a latent class analysis

Addiction Research and Theory

Volumn 17, Issue 2, 2009, Pages 168-185

  Patra, Jayadeep ^a,b   Fischer, Benedikt ^a,b,c   Maksimowska, Sandy ^a   Rehm, Jürgen ^a,b,d  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF VICTORIA   (Canada)

^d Institut fur Sucht und Gesundheitsforschung Zurich   (Switzerland)

Author keywords

Canada; IDU; Latent class analysis; OPICAN; Poly substance

Indexed keywords

EID: 68249141220     PISSN: 16066359     EISSN: 14767392     Source Type: Journal    
DOI: 10.1080/16066350802372827     Document Type: Article

References (86)

1. Agrawal A, Lynskey MT, Madden PAF, Bucholz KK, Heath AC. 2006. A latent class analysis of illicit drug abuse/dependence: Results from the National Epidemiological survey on alcohol and related conditions. Addiction 102:94-104.
2. Barrett SP, Gross SR, Garand I, Pihl RO. 2005. Patterns of simultaneous polysubstance use in Canadian rave attendees. Substance use & misuse 40:1525-1537.
3. Baumer E, Lauritsen J, Rosenfeld R, Wright R. 1998. The influence of crack cocaine on robbery, burglary and homicide rates: A cross-city longitudinal analysis. Journal of Research on Crimes & Deliquencies 35(3):316-340.
4. Best D, Sidwell C, Gossop M, Harris J, Strang J. 2001. Crime and expenditure amongst polydrug misusers seeking treatment: The connection between prescribed methadone and crack use, and criminal involvement. British Journal of Criminology 41:119-126.
5. Bickel WK, Kelly TH. 1988. The relationship of stimulus control to the treatment of substance abuse. In: Ray BA, editor. Learning Factors in Substance Abuse. Washington, DC: US Government Printing Office. pp 122-140.
6. Byqvist S. 2007. Patterns of drug use among drug misusers in Sweden. Gender differences. Substance use & misuse 41:1817-1835.
7. Cicero TJ, Inciardi JA, Munoz A. 2005. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. Journal of Pain 6:662-672.
8. Coffin P, Galea S, Ahern J, Leon A, Vlahov D, Tardiff K. 2003. Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990-98. Addiction 98(6):739-747.
9. Compton W, Volkow N. 2006. Major increases in opioid analgesic abuse in the United States: Concerns and strategies. Drug & Alcohol Dependence 81:103-107.
10. Condelli WS, Fairbank JA, Dennis ML, Rachal JV. 1991. Cocaine use by clients in methadone programs: Significance, scope, and behavioral interventions. Journal of Substance Abuse Treatment 8(4):203-12.
11. Cone EJ, Fant RV, Rohay JM, Caplan YH, Ballina M, Reder RF, Spyker D, Haddox JD. 2004. Oxycodone involvement in drug abuse deaths: II. Evidence for toxic multiple drug-drug interactions. Journal of Analytical Toxicology 28:616-624.
12. Crabbe, JC (2002) Genetic contribution to addiction. Annual Review of Psychology, 53, pp. 435-462.
13. D'Aunno T, Vaughn TE. 1992. Variations in methadone treatment practices. Results from a national study. Journal of American Medical Associaion 267(2):253-258.
14. de Vos JW, Ufkes JGR, van Brussel GHA, van den Brink W. 1996. Craving despite extreme high methadone dosage. Drug Alcohol Dependence 40(3):181-184.
15. Dillon P, Copeland J, Jansen K. 2003. Patterns of use and harms associated with non-medical ketamine use. Drug & Alcohol Dependence 69:23-28.
16. Fischer B, Kirst M, Rehm J, Marsh D, Bondy S, Tyndall M. 2000b. The phenomenon of so-called 'other drug use' among opiate addicts in the North American context: Evidence, consequences, questions. In: Westermann B, Bellman GU, Jellinek C, editors. Beigebrauch: Offene Grenzen der Substitution. Beltz: Deutscher Studien Verlag. pp 95-118.
17. Fischer B, Medved W, Gliksman L, Rehm J. 1999. Illicit opiates in Toronto: A profile of current users. Addiction Research 7(5):377-415.
18. Fischer B, Rehm J. 2007a. Illicit opioid use in the 21st century: Witnessing a paradigm shift? Addiction 102(4):499-501.
19. Fischer B, Rehm J. 2007b. Understanding the parameters of non-medical use of prescription drugs: moving beyond mere numbers. Addiction 102(12):1931-1932.
20. Fischer B, Rehm J, Blitz-Miller T. 2000a. Injection drug use and preventive measures: a comparison of Canadian and Western European jurisdictions over time. Canadian Medical Association Journal 162(12):1709-1713.
21. Fischer B, Rehm J, Brissette S, Brochu S, Bruneau J, el-Guebaly N, Noel L, Tyndall MW, Wild C, Mun P, et al. 2005a. Illicit opioid use in Canada - Comparing social, health and drug use characteristics of untreated users in five cities (OPICAN Study). Journal of Urban Health 82(2):250-266.
22. Fischer B, Monga N, Manzoni P. 2005b. Differences between co-users of cocaine and crack among Canadian illicit opioid users. Sucht 51(4):217-224.
23. Fischer, B., Rehm, J., Patra, J. and Firestone-Cruz, M. 2006a. Changes in illicit opioid use across Canada. Canadian Medical Association Journal, 175(11):1385-1387.
24. Fischer B, Rehm J, Patra J, Kalousek K, Haydon E, Tyndall M, El-Guebaly N. 2006b. Crack across Canada: Comparing crack users and crack non-users in a Canadian multi-city cohort of illicit opioid users. Addiction 101(12):1760-1770.
25. Frank B, Galea J. 1996. Cocaine trends and other drug trends in New York City, 1986-94. Journal of Addictive Disease 15:1-12.
26. Frick U, Rehm J, Kovacic S, Ammann J, Uchtenhagen A. 2006. A prospective cohort study on orally administered heroin substitution for severely addicted opioid users. Addiction 101(11):1631-9.
27. Gesundheit, Bundesamt für (Ed). Handbuch Heroingestützte Behandlung. Richtlinien, Empfehlungen, Information. Bern: Bundesamt für Gesundheit, 2000.
28. Gonzalez G, Sevaroni K, Sofuoglu M, Poling J, Oliveto A, Gonsai K, George TP, Kosten TR. 2003. Tiagabine increasesCornish & kalivas, 2005 cocaine-free urines in cocaine-dependent methadone-treated patients: results from a randomized pilot study. Addiction 98:1625-1632.
29. Gossop M, Marsden J, Stewart D. 2002. Dual dependence: assessment of dependence upon alcohol and illicit drugs, and the relationship of alcohol dependence among drug misusers to patterns of drinking, illicit drug use and health problems. Addiction 97:169-178.
30. Grella CE, Anglin MD, Wugalter SE. 1995. Cocaine and crack use and HIV risk behaviours among high-risk methadone maintenance clients. Drug & Alcohol Dependence 37:15-21.
31. Grella CE, Anglin MD, Wugalter SE. 1997. Patterns and predictors of cocaine and crack use by clients in standard and enhanced methadone maintenance treatment. American Journal of Drug & Alcohol Abuse 23:15-42.
32. Hall W, Degenhardt L, Lynskey M. 1999. Opioid overdose mortality in Australia, 1964-1997: Birth-cohort trends. Medical Journal of Australia 171:34-37.
33. Hall W, Lynskey M, Degenhardt L. 2000. Trends in opiate-related deaths in the United Kingdom and Australia, 1985-1995. Drug & Alcohol Dependence 52:71-77.
34. Haney M, Hart CL, Foltin RW. 2006. Effects of baclofen on cocaine self-administration: Opioid- and nonopioid-dependent volunteers. Neuropsychopharmacology 31(8):1814-1821.
35. Harrison L. 1995. The validity of self-reported data on drug use. Journal Of Drug Issues 25(1):91-111.
36. Hartel DM, Schoenbaum EE, Selwyn PA, Kline J, Davenny K, Klein RS, Friedland GH. 1995. Heroin use during methadone maintenance treatment: The importance of methadone dose and cocaine use. American Journal of Public Health 85:83-88.
37. Hausser D, Kubler D, Dubois-Arber F. 1999. Characteristics of heroin and cocaine users unknown to treatment agencies. Results from the Swiss Hidden Population Study. Sozia- und Präventivmed 44:222-232.
38. Haydon E, Fischer B. 2005. Crack use as a public health problem in Canada - Call for an evaluation of "safer crack use kits. Canadian Journal of Public Health 96:185-188.
39. Inciardi JA, Surratt HL, Kurtz SP, Cicero TJ. 2007. Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Medicine 8(2):171-183.
40. Joe GW, Simpson DD. 1995. HIV risks, gender, and cocaine use among opiate users. Drug & Alcohol Dependence 37:23-28.
41. Judd A, Hutchinson S, Wadd S, Hickman M, Taylor A, Jones S, Parry JV, Cameron S, Rhodes T, Ahmed S, et al. 2005. Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: Cross sectional analysis. Journal of Viral Hepatitis 12(6):655-62.
42. Kandel DB, Yamaguchi K, Chen K. 1992. Stages of progression in drug involvement from adolescence to adulthood: Further evidence for the Gateway Theory. Journal of Studies on Alcohol 53(5):447-457.
43. Kandel DB, Yamaguchi K. 1993. From beer to crack: Developmental patterns of drug involvement. American Journal of Public Health 83(6):851-855.
44. Kaufman E. 1976. The abuse of multiple drugs: I. Definition, classification and extent of problem. American Journal of Drug & Alcohol Abuse 3(2):279-292.
45. Kenna GA, Nielsen DM, Mello P, Schiesl A, Swift RM. 2007. Pharmacotherapy of dual substance abuse and dependence. CNS Drugs 21(3):213-237.
46. Kerr T, Tyndall M, Li K, Montaner J, Wood E. 2005. Safer injection facility use and syringe sharing in injection drug users. Lancet 366(9482):316-318.
47. Kramer CY. 1956. Extension of multiple range tests to group means with unequal numbers of replications. Biometrics 12:309-310.
48. Kreek MJ. 1997. Opiate and cocaine addictions: Challenge for pharmacotherapies. Pharmacology Biochemistry & Behavior 57(3):551-569.
49. Lauzon P, Vincelette J, Bruneau J, Lamothe F, Lachance N, Brabant M, Soto J. 1994. Illicit use of methadone among i.v. drug users in Montreal. Journal of Substance Abuse Treatment 11:457-461.
50. Leri F, Stewart J. 2001. Drug-induced reinstatement to heroin and cocaine seeking: A rodent model of relapse in polydrug use. Experimental & Clinical Psychopharmacology 9:297-306.
51. Leri F, Bruneau J, Stewart J. 2003. Understanding polydrug use: Reviewing heroin and cocaine co-use. Addiction 98(1):7-22.
52. Leri F, Stewart J, Fischer B, Rehm J, Marsh DC, Brissette S, Bruneau J, El-Guebaly N, Noel L, Tyndall MW, et al. 2005. Patterns of opioid and cocaine co-use: A descriptive study in a Canadian sample of untreated opioid-dependent individuals. Experimental & Clinical Psychopharmacology 13(4):303-310.
53. Lo Y, Mendell N, Rubin D. 2001. Testing the number of components in a normal mixure. Biometrika, 88:767-778.
54. Lynskey MT, Agrawal A, Bucholz KK, Nelson EC, Madden PA, Todorov AA, Grant JD, Martin NG, Health AC. 2006. Subtypes of illicit drug users: A latent class analysis of data from an Austrlian Twin sample. Twin Research & Human Genetics 9(4):523-530.
55. McCutcheon A. 1987. Latent class analysis. Newbury Park, CA: Sage.
56. Miller CL, Kerr T, Strathdeel SA, Li, Kathy, Wood E. 2007. Factors associated with premature mortality among young injection drug users in Vancouver. Harm Reduction, Journal 4(1).
57. Millson P, Myers T, Calzavara L, Wallace E, Major C, Degani N. 2003. Regional variation in HIV prevalence and risk behaviours in Ontario injection drug users (IDU). Canadian Journal of Public Health 94(6):431-435.
58. Milloy MJ, Wood E, Small W, Tyndall M, Lai C, Montaner J, Kerr T. 2008. Incarceration experiences in a cohort of active injection drug users. Drug Alcohol Rev 31:1-7.
59. Monga N, Rehm J, Fischer B, Brissette S, Bruneau J, El-Guebaly N, Noel L, Tyndall M, Wild C, Leri F, et al. 2007. Using latent class analysis (LCA) to analyze patterns of drug use in a population of illegal opioid users. Drug & Alcohol Dependence 88:1-8.
60. Muthen LK, Muthen BO. 2006. Mplus User's Guide. 4th ed.. Los Angeles, CA: Muthen & Muthen.
61. Nahas G. 1990. Keep off the grass. Middlebury, VT: P.S. Eriksson.
62. Nylund KL, Asparouhov T, Muthen B. 2007. Deciding on the number of classes in latent class analysis and growth mixture modeling. A monte carlo simulation study. Available from: http://www.statmodel.com/download/LCA_tech11_nylund_v83.pdf [accessed on April 30, 2007].
63. Oetting ER, Beauvais R. 1990. Adolescent drug use: Findings of national and local surveys. Journal of Consulting and Clinical Psychology 58:385-394.
64. Operario D, Choi KH, Chu PL, McFarland W, Secura GM, Behel S, MacKellar D, Valleroy L. 2006. Prevalence and correlates of substance use among young Asian Pacific Islander men who have sex with men. Preventive Science 7:19-29.
65. Patterson TL, Semple SJ, Zians JK, Strathdee SA. 2005. Methamphetamine-using HIV-positive men who have sex with men: Correlates of polydrug use. Journal of Urban Health 82(Suppl. 1):126.
66. Plomin R, Crabbe J. 2000. DNA. Psychology Bulletin 126:806-828.
67. Raftery, A.E. 1995. Bayesian model selection in social research (with discussion by Andrew Gelman, Donald B Rubin and Robert M Hauser). In PV Marsden, editor. Social Methodology. Blackwells, Oxford, pp. 111-196.
68. Rawson RA, McCann MJ, Hasson AJ, Ling W. 1994. Cocaine abuse among methadone maintenance patients: Are there effective treatment strategies? Journal of Psychoactive Drugs 26(2):129-36.
69. Ross J, Darke S. 2000. The nature of benzodiazepine dependence among heroin users in Sydney, Australia. Addiction 95:1785-1793.
70. Roy E, Haley N, Leclerc P, Boivin JF, Cedras L, Vincelette J. 2001. Risk factors for hepatitis C virus infection among street youths. Canadian Medical Association Journal 165(5):557-60.
71. Rowlett JK, Negus SS, Shippenberg TS, Mello NK, Walsh SL, Spealman RD. 1997. Combined cocaine and opioid abuse: From neurobiology to the clinic. NIDA Research Monographs 178:55-57.
72. Schifano F, Oyefeso A, Corkery J, Cobain K, Jambert-Gray R, Martinotti G, Ghodse A. 2003. Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996-2002. Human Psychopharmacology 18:519-524.
73. Schottenfeld RS, O'Malley S, Abdul-Salaam K, O'Connor PG. 1993. Decline in intravenous drug use among treatment-seeking opiate users. Journal of Substance Abuse & Treatment 10:5-10.
74. Schutz CG, Vlahov D, Anthony JC, Graham NM. 1994. Comparison of self-reported injection frequencies for past 30 days and 6 months among intravenous drug users. Journal of Clinical Epidemiology 47(2):191-195.
75. Shearer J, Gowing L. 2004. Pharmacotherapies for problematic psychostimulant use: a review of current research. Drug and Alcohol Review 23(2):203-211.
76. Sofuoglu M, Kosten TR. 2005. Novel approaches to the treatment of cocaine addiction. CNS Drugs 19(1):13-25.
77. SPSS Inc. SPSS System for Windows, Version 15. Chicago, IL; 2006-2007.
78. Stallings MC, Corley RP, Hewitt JK, Krauter KS, Lessem JM, Mikulich SK, Rhee SH, Smolen A, Young SE, Crowley TJ. 2003. A genome-wide search for quantitative trait loci influencing substance dependence vulnerability in adolescence. Drug & Alcohol Dependence 70:295-307.
79. Stallings MC, Corley RP, Hewitt JK, Krauter KS, Lessem JM, Mikulich SK, Rhee SH, Smolen A, Young SE, Crowley TJ. 2003. A genome-wide search for quantitative trait loci influencing substance dependence vulnerability in adolescence. Drug and Alcohol Dependence 70:295-307.
80. Stoltz JA, Wood E, Small W, Li K, Tyndall M, Montaner J, Kerr T. 2007. Changes in injecting practices associated with the use of a medically supervised safer injection facility. Journal of Public Health 29(1):35-39.
81. Suh JJ, Pettinati HM, Kampman KM, et al. 2006. The status of disulfiram: A half of a century later. Journal of Clinical Psychopharmacology 26(3):290-302.
82. Tyndall MW, Currie S, Johnston C, Li K, O'Shaughnessy M, Schechter MT. 2000. Changing patterns of drug use: Vancouver, Canada - 1996 to 1999 (abstract 347P). Canadian Journal of Infectious Diseases 11(Suppl B):66B.
83. Tyndall MW, Currie S, Spittal P, Li K, Wood E, O'Shaughnessy M, Schechter, M. 2003. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. Aids, 17:887-893.
84. Uhl GR, Liu QR, Walther D, Hess J, Naiman D. 2001. Polysubstance abuse vulnerability genes: Genome scans for association using 1,004 subjects and 1,494 single-nucleotide polymorphisms. American Journal of Human Genetics 69:1290-1300.
85. van den Brink W, van Ree JM. 2003. Pharmacological treatments for heroin and cocaine addiction. Eur Neuropsychopharmacol 13(6):476-87.
86. Wood E, Tyndall MW, Qui Z, Zhang R, Montaner JS, Kerr T. 2006. Service uptake and characteristics of injection drug users utilizing North America's first medically supervised safer injecting facility. American Journal of Public Health 96(5):770-773.